Verona Pharma
Clinical trials sponsored by Verona Pharma, explained in plain language.
A biopharmaceutical company developing respiratory therapies, now a subsidiary of Merck.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New inhaler drug shows promise for COPD inflammation Results expected Dec 2026 (estimated)
-
New combo inhaler aims to improve breathing in COPD patients
Disease control CompletedThis study tests a new fixed-dose combination of two drugs (ensifentrine and glycopyrrolate) given via nebulizer twice daily for 28 days in 480 adults with COPD. The goal is to see if the combination improves lung function more than either drug alone or placebo. The trial is curr…
Phase 2 • Sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New COPD inhaler shows promise in early trial
Disease control CompletedThis study tested an inhaled medication called glycopyrrolate in 46 people with COPD. Participants received three different doses of the drug and a placebo over separate one-week periods. The goal was to see if the drug improves lung function and is safe. This is an early-stage t…
Phase 2 • Sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New COPD combo shows promise in early trial
Disease control CompletedThis study tested a new combination of two inhaled drugs, ensifentrine and glycopyrrolate, in 33 adults with COPD. The goal was to see how the drugs move through the body, how well they open airways, and if they are safe. Each person received single doses of the combination and e…
Phase 2 • Sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC